Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
Stanley Cohan1,2,3 1Providence Multiple Sclerosis Center, 2Providence Brain and Spine Institute, 3Providence Health & Services, Portland, OR, USA Abstract: Despite the availability of multiple disease-modifying therapies for relapsing multiple sclerosis (MS), there remains a need for highly...
Guardado en:
Autor principal: | Cohan S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2a044b93820402db845b0bff30c7a2d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
por: Tran JQ, et al.
Publicado: (2016) -
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
por: Elsbernd PM, et al.
Publicado: (2021) -
Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
por: Konrad Rejdak, et al.
Publicado: (2021) -
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Sylwia Pietrasik, et al.
Publicado: (2021) -
Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
por: Ratthaporn Boonsuth, et al.
Publicado: (2021)